Slate Medicines
Tracked across 1 events · 6 articles · First seen Aug 17, 2026 · Last active Aug 19, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Slate Medicines is the acquirer in the merger, bringing its migraine pipeline including lead candidate SLTE-1009. The combined company will operate under Slate's name and management, with Slate shareholders owning about 95% of the entity.
Aug 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Slate Medicines live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard